Why There Is No Settlement Yet — and When to Expect One
MDL 2921 is moving toward its first bellwether trial in October 2026. In most major product liability MDLs, global settlement negotiations do not conclude until after bellwether trial results are known — the trial data gives both sides empirical information about how juries evaluate the claims. Mediation has been ongoing between Allergan/AbbVie and plaintiffs' leadership counsel throughout 2024 and 2025, but no settlement framework has been publicly announced as of February 2026. Once the October 2026 bellwether trial produces a verdict or pretrial settlement, settlement negotiations are expected to accelerate rapidly, as occurred in the metal-on-metal hip implant MDLs that settled in the $2–4 billion range globally.
Factors That Determine Settlement Value in BIA-ALCL Cases
The factors that most significantly affect individual claim value in MDL 2921 are: BIA-ALCL stage at diagnosis (Stage IA through IV — the single most important factor); treatment required (surgery only vs. surgery plus chemotherapy vs. stem cell transplant); long-term prognosis (remission vs. ongoing disease); age at diagnosis; whether the implants were for cosmetic augmentation or post-mastectomy reconstruction (reconstruction cases carry stronger sympathy and additional damages); documented medical expenses and lost earnings; and the emotional impact including the psychological burden of a cancer diagnosis from an elective or reconstructive medical device. Wrongful death cases from BIA-ALCL command the highest settlement values and incorporate the full range of wrongful death damages available under applicable state law.
Estimated Settlement Ranges by Stage
Based on comparable medical device mass tort outcomes and emerging MDL 2921 case valuations, estimated ranges are: Stage IA (seroma-confined, surgery only) — $50,000 to $300,000. Stage IB–IIA (capsule or single lymph node involvement, surgery plus chemotherapy) — $300,000 to $900,000. Stage IIB–III (multiple lymph nodes or adjacent structure involvement) — $600,000 to $1,500,000. Stage IV (metastatic disease) — $1,000,000 to $3,000,000 or more. Wrongful death — $1,500,000 to $5,000,000 or more depending on decedent's age, dependents, and medical expenses. Explant-only cases (no BIA-ALCL diagnosis) — $10,000 to $150,000 depending on surgery costs and documented harms. These are estimates only. Actual settlement values will be determined by the outcome of bellwether trials and the terms of any global settlement grid negotiated by MDL leadership.
Frequently Asked Questions
Related Pages
BIA-ALCL is not breast cancer — it is a T-cell lymphoma of the immune system that develops in the fluid or capsule surrounding Allergan BIOCELL textured implants. It is often curable when caught early, but advanced stages require chemotherapy and carry serious health consequences.
Learn moreBIA-ALCL staging — from Stage IA (confined to seroma fluid) through Stage IV (distant metastases) — is the single most important factor in determining the value of an Allergan breast implant lawsuit. Early-stage cases are curable; advanced stages require chemotherapy and carry worse prognosis and significantly higher compensation.
Learn moreThe July 24, 2019 Allergan BIOCELL recall was the largest breast implant recall in FDA history. It covered 33+ product lines after the FDA determined BIOCELL recipients faced a 6x elevated risk of BIA-ALCL lymphoma. French regulators had recalled the same product a year earlier in 2018.
Learn moreBreast implant illness (BII) is a constellation of systemic symptoms — fatigue, brain fog, joint pain, hair loss — reported by implant patients. Unlike BIA-ALCL, BII is not yet a formally recognized diagnosis, but BII plaintiffs with Allergan BIOCELL implants are included in MDL 2921 litigation.
Learn moreThe Allergan Natrelle 410 Highly Cohesive Anatomically Shaped implant was the most widely used recalled product and is at the center of MDL 2921. McGhan textured implants — an earlier Allergan brand — are also covered by the July 2019 recall. If you received either product, you may have a claim.
Learn moreWomen who received Allergan BIOCELL textured implants or tissue expanders as part of post-mastectomy breast reconstruction after breast cancer are a distinct and especially sympathetic plaintiff class in MDL 2921. They fought breast cancer once — and Allergan's recalled product put them at risk of a second cancer.
Learn moreThe FDA does not recommend prophylactic removal of Allergan BIOCELL implants for asymptomatic patients. However, women who chose explantation after the recall may have legal claims for surgery costs. Women with BIA-ALCL symptoms require immediate medical evaluation — not observation.
Learn moreThe statute of limitations for Allergan BIOCELL claims is typically 2 to 3 years from discovery — meaning from BIA-ALCL diagnosis, not from implant placement or recall date. Discovery rule protections apply in most states. Consult an attorney immediately — deadlines are strict and MDL tolling is not automatic.
Learn moreYou may qualify if you received Allergan BIOCELL textured implants (for augmentation or reconstruction), were diagnosed with BIA-ALCL, or had your implants removed due to the recall. You do not need a cancer diagnosis to file. Implants already removed do not disqualify you.
Learn moreAllergan Breast Implant Lawsuit Lawsuit
Allergan (now owned by AbbVie) manufactured BIOCELL textured breast implants — including the widely used Natrelle 410 — that were found to cause breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious T-cell lymphoma of the immune system. The FDA determined that women with Allergan BIOCELL implants were approximately six times more likely to develop BIA-ALCL than women with implants from other manufacturers. On July 24, 2019, Allergan initiated a worldwide recall of all BIOCELL textured breast implants and tissue expanders. As of June 2023, the FDA had received 1,264 BIA-ALCL reports globally, with 1,079 — representing 85% of all cases — involving Allergan implants. Sixty-three deaths have been reported, with 37 linked to Allergan products. MDL 2921, In re Allergan BIOCELL Textured Breast Implant Products Liability Litigation, is pending before Judge Michael Martinotti in the District of New Jersey with approximately 1,400 cases. The first bellwether trial is scheduled for October 2026. Women who received Allergan BIOCELL textured implants, were diagnosed with BIA-ALCL, or underwent implant removal due to the recall may have viable legal claims.
View full case overview